Gyre Therapeutics (GYRE) Gross Profit (2020 - 2026)

Gyre Therapeutics (GYRE) has reported Gross Profit for 7 consecutive years, with $21.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 0.6% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $111.3 million (up 14.93% YoY), while the FY2025 annual figure was $111.2 million, up 9.13% from the prior year.
• Gross Profit declined to $21.3 million in Q1 2026 per GYRE's latest filing, from $35.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $97.5 million in Q4 2022 and bottomed at -$4000.0 in Q1 2022.
• Historically, Gross Profit has averaged $29.4 million across 5 years, with a median of $25.9 million in 2023.
• On a YoY basis, Gross Profit climbed as much as 595250.0% in 2023 and fell as far as 73.44% in 2023.
• Gyre Therapeutics' Gross Profit stood at $97.5 million in 2022, then slumped by 73.44% to $25.9 million in 2023, then climbed by 3.08% to $26.7 million in 2024, then soared by 32.8% to $35.5 million in 2025, then sank by 39.94% to $21.3 million in 2026.
• Business Quant data shows GYRE's Gross Profit at $21.3 million in Q1 2026, $35.5 million in Q4 2025, and $28.9 million in Q3 2025.